reports
- Anas Fitri Bin Ahmad
- Audrey Celia
- Bella Lu Yifei
- Colin Lee
- Ejann Hiew
- Heidi Mo Jinghui
- Jack Goh Tooan Orng
- John Cheong Ming Chern
- Johnny Yum Chung Man
- Ken Lee
- Kitpon Praipaisarnkit
- Lester Siew
- Shirley Wang Xueyi
- Stella Guo Yuting
- Thanawat Thangchadakorn
- Willinoy Sitorus
Regional Morning Meeting Notes: Wednesday, August 20, 2025
GREATER CHINA Results China Resources Beer (291 HK/BUY/HK$28.28/Target: HK$33.80): 1H25: Results beat; Heineken and sub-premium the core for next stage. Guangzhou Tinci Materials Technology (002709 CH/BUY/Rmb20.60/Target: Rmb30.00): 2Q25: Earnings miss on ASP and margins; Maintain BUY. Cut target price from Rmb39.60 to Rmb30.0. Xiaomi Corp (1810 HK/BUY/HK$52.40/Target: HK$69.20): 2Q25: Record-high bottom line; EV business to be boosted by YU7 deliveries. Maintain BUY. XPeng Inc (9868 HK/BUY/HK$7...
- Audrey Celia
- Willinoy Sitorus
Kalbe Farma (KLBF IJ) - Expect Margins To Normalise In 2H25
KLBF has reduced its guidance for 2025 revenue and net profit to 6-8% (from 8-10% previously), while still remaining cautiously optimistic (our estimates are slightly higher). Its specialty pharma should be one of its key growth drivers, while its nutritional segment is still facing stiff competition. Maintain BUY with a target price of Rp1,800.
- Audrey Celia
- Maskun Ramli
- Willinoy Sitorus
- Johnny Yum
Strategy - Alpha Picks: Underperformance In July
In Jul 25, our portfolio underperformed the JCI by -11.1%, mainly due to the rally in conglomerate-related stocks (with the largest contributors being DCII, BREN, BRPT, DSSA and CDIA). Assuming no price movement in the top 10 conglomerate-related stocks, our portfolio underperformed the JCI by -5.3%. Events to monitor next week include Indonesia’s 2Q25 GDP figure and MSCI announcements on 5 and 7 August. Our new Alpha Picks are ASSA, AKRA, ARCI, BBNI, MTEL, KLBF and MYOR.
- Johnny Yum
- Maskun Ramli
- Audrey Celia
- Carol Dou Xiao Qin
- Chong Lee Len
- Claire Wang Kelai
- Jonathan Koh
- Posmarito Pakpahan
- Sunny Chen
- Wei Xiang Ku
- Willinoy Sitorus
- Ziv Ang Sze Champ
Regional Morning Meeting Notes: Monday, July 28, 2025
GREATER CHINA Update Baoshan Iron & Steel (600019 CH/BUY/Rmb7.44/Target: Rmb8.20) Riding the policy wave, watching for undercurrents. Shenzhen Mindray Bio-Medical Electronics (300760 CH/BUY/Rmb231.84/Target: Rmb325.00) Regaining growth momentum from Q3 2025, on track for top 10 global medtech status. INDONESIA Sector Consumer 2Q25 preview: Mixed results. Results Bank Negara Indonesia (BBNI IJ/BUY/Rp4,090/Target: Rp5,...
KLBF PT KALBE FARMA TBK
AMRT SUMBER ALFARIA TRIJAYA TBK PT
AJBU KEPPEL DC REIT
MYOR MAYORA INDAH
MAPI MITRA ADIPERKASA
ERAA ERAJAYA SWASEMBADA
ACES PT ACE HARDWARE INDONESIA TBK
600019 BAOSHAN IRON & STEEL CO. LTD. CLASS A
MLK MALAKOFF CORP BHD
ICBP INDOFOOD CBP SUKSES MAKMUR T
300760 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO. LTD. CLASS A
CTOS CTOS DIGITAL BHD
BBNI BANK NEGARA INDONESIA PERSER
CMRY PT CISARUA MOUNTAIN DAIRY TBK
- Audrey Celia
- Willinoy Sitorus
Consumer – 2Q25 Preview: Mixed Results
Despite macroeconomic headwinds, we expect 1H25 results across the consumer sector to reflect resilient momentum in selective segments, with performance diverging by product category, pricing power, margin management and adaptability. While weak purchasing power likely weighed on mass-market demand, easing soft commodity prices may improve sentiment. We upgrade the sector to OVERWEIGHT. Top picks: KLBF, CMRY and ERAA.
- Audrey Celia
- Maskun Ramli
- Posmarito Pakpahan
- Willinoy Sitorus
Indonesia Daily - Monday, July 28, 2025
Consumer: 2Q25 preview: Mixed results. Bank Negara Indonesia (BBNI IJ/BUY/Rp4,090/Target: Rp5,100): 2Q25: NIM likely to have bottomed, with recovery expected in 2H25. TRADERS’ CORNER Tower Bersama Infrastructure (TBIG IJ): Technical BUY Indofood CBP Sukses Makmur (ICBP IJ): Technical BUY
- Carol Dou Xiao Qin
- Gigi Cheuk
- Heidi Mo Jinghui
- Jack Lai Yuan Khai
- John Cheong Ming Chern
- Julia Pan Mengyao
- Kate Luang
- Lester Siew
- Ming San Soong
- Sunny Chen
- Thanawat Thangchadakorn
- Willinoy Sitorus
Regional Morning Meeting Notes: Thursday, June 19, 2025
GREATER CHINA Sector Healthcare Entering a new phase of accelerated growth. Upgrade to OVERWEIGHT. Internet 618 Festival – Evolving consumer trends and continued focus on value for money. Small/Mid Cap Highlights JBM Healthcare (2161 HK/BUY/HK$2.85/Target: HK$3.31) Takeaways from luncheon. INDONESIA Update Kalbe Farma (KL...
BBL BANGKOK BANK PUBLIC COMPANY LIMITED
01093 CSPC PHARMACEUTICAL GROUP LIMITED
KTB KRUNG THAI BANK PUBLIC CO. LTD.
TISCO TISCO FINANCIAL GROUP
300015 AIER EYE HOSPITAL GROUP CO. LTD. CLASS A
KLBF PT KALBE FARMA TBK
00241 ALIBABA HEALTH INFORMATION TECHNOLOGY LTD.
TMB TMB BANK PUBLIC COMPANY LIMITED
KBANK KASIKORNBANK PUBLIC CO. LTD.
01177 SINO BIOPHARMACEUTICAL LIMITED
4731 SCIENTEX
X2S SINOPHARM GROUP CO. LTD. CLASS H
SCI SCI ELECTRIC
PDD PINDUODUO INC. SPONSORED ADR CLASS A
3933 THE UNITED LABORATORIES INTE
KLK KUALA LUMPUR KEPONG BHD
2877 CHINA SHINEWAY PHARMACEUTICA
HCM HUTCHISON CHINA MEDITECH LIMITED
01801 INNOVENT BIOLOGICS INC.
1833 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED
300760 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO. LTD. CLASS A
603882 GUANGZHOU KINGMED DIAGNOSTICS GROUP CO. LTD. CLASS A
RSTON RIVERSTONE HOLDINGS LTD
1093 CSPC PHARMACEUTICAL GROUP LTD
603259 WUXI APPTEC CO. LTD. CLASS A
09988 ALIBABA GROUP HOLDING LTD.
2269 WUXI BIOLOGICS (CAYMAN) INC.
09618 JD.COM INC. CLASS A
3692 HANSOH PHARMACEUTICAL GROUP
01024 KUAISHOU TECHNOLOGY CLASS B
06160 BEIGENE LTD.
SCB WUXI APPTEC CO. LTD. CLASS H
300765 SCB X PUBLIC COMPANY LIMITED
02161 CSPC INNOVATION PHARMACEUTICAL CO L
300244 JBM (HEALTHCARE) LTD
TTB DIAN DIAGNOSTICS GROUP CO
TOTAL BRAIN LTD
- Willinoy Sitorus
Kalbe Farma (KLBF IJ) - Well-Diversified Defensive Stock; Innovation A...
Share price has increased by 13.6% since KLBF released its 1Q25 results on 30 Apr 25 following a solid performance (net profit rose 12.5% yoy and accounted for 30% of both our and consensus 2025 estimates), supported by margin expansion. KLBF guides an 8- 10% revenue growth in 2025, with prescription pharma as the key driver. We remain constructive on KLBF’s prospects, given its well-diversified business segments, ongoing innovation and continued expansion. Maintain BUY. Target price: Rp1,800.
- Maskun Ramli
- Willinoy Sitorus
- Johnny Yum
Strategy - Alpha Picks: Underperformance In Feb 25
Our portfolio underperformed in Feb 25, declining 17.1% as JCI dropped 11.8% to a three-year low. There was a sell-off on banking stocks as investors were concerned that being included in Danantara could result in a similar fate to state-owned construction companies. Due to a sharp rise in DCII, IDXTECH outperformed in Feb 25. We remove BMRI, ISAT and CTRA from our portfolio and add MIKA. Our picks are BBNI, BBRI, MIKA, EXCL, KLBF, JSMR and ASII.
- Johnny Yum
- Maskun Ramli
- Benjaphol Suthwanish
- Colin Lee
- Damon Shen
- Gigi Cheuk
- Jieqi Liu
- Johnny Yum Chung Man
- Jonathan Koh
- Julia Pan Mengyao
- Kasemsun Koonnara
- Kate Luang
- Kitpon Praipaisarnkit
- Kong Ho Meng
- Lester Siew
- Ming San Soong
- Stevanus Juanda
- Tanaporn Visaruthaphong
Regional Morning Notes - Tuesday, February 18, 2025
GREATER CHINA Strategy China And Hong Kong Property: Observations of 2025 Chinese New Year: Weakened new-home sales in Jan 25 and low growth in tourists to Hong Kong; further policy support is needed and possible. Sector Education: Widespread AI adoption to fuel education sector’s monetisation growth. Update Xiaomi Corp (1810 HK/BUY/HK$45.15/Target: HK$52.40): 4Q24 results preview: expect solid beat across all four segments. Maintain BUY. Small-mid Cap Highlight Cheerwin Group (6601 HK/NOT RATED...
- Stevanus Juanda
Kalbe Farma (KLBF IJ) - Expect 8-10% NPAT Growth In 2025; Trading Belo...
KLBF guides an indicative 17.2% yoy growth in 2024 NPAT. Compared with the implied NPAT of Rp3,243b, this indicates in-line results vs consensus forecasts of Rp3.2t. For 2025, NPAT growth is estimated at 8-10% yoy. The pharmaceutical and distribution divisions are expected to report strong growth, consumer health should see a singledigit growth, while nutritional sales should be flat. Maintain BUY with KLBF as our top pick in the pharmaceutical sector. Target price: Rp1,800 (40.1% upside).
- Maskun Ramli
- Stevanus Juanda
- Arsit Pamaranont
- Damon Shen
- Jieqi Liu
- Johnny Yum
- Jonathan Koh
- Julia Pan Mengyao
- Kasemsun Koonnara
- Ming San Soong
- Stevanus Juanda
- Tanaporn Visaruthaphong
Regional Morning Meeting Notes: Tuesday, February 11, 2025
GREATER CHINA Sector Internet Growth potential and AI development trends following emergence of DeepSeek. Property Policy implementation and development remain the key focus and catalyst. INDONESIA Strategy Catching A Falling Knife Or Opportunity To Buy? We Say Buy Our picks are BBCA, BBTN, CMRY, ICBP, KLBF, CTRA, AMRT, PGEO, TL...
ORI ORIGIN PROPERTY
00688 CHINA OVERSEAS LAND & INVESTMENT LIMITED
D05 DBS GROUP HOLDINGS LTD
01109 CHINA RESOURCES LAND LIMITED
CTRA CIPUTRA DEVELOPMENT
AMATA AMATA CORP
IRPC IRPC PUBLIC CO. LTD.
ISAT INDOSAT
QH QUALITY HOUSES
3K1 KINGSOFT CORP. LTD.
SCNR SUNAC CHINA HOLDINGS LTD.
RLF LONGFOR GROUP HOLDINGS LTD.
KLBF PT KALBE FARMA TBK
AMRT SUMBER ALFARIA TRIJAYA TBK PT
SPALI SUPALAI PCL
ICBP PT INDOFOOD CBP SUKSES MAKMUR TBK
AP AP THAILAND
00700 TENCENT HOLDINGS LTD.
LPN LPN DEVELOPMENT PCL
PSH PRUKSA HOLDING PCL
09988 ALIBABA GROUP HOLDING LTD.
09888 BAIDU INC
BBTN BANK TABUNGAN NEGARA PERSERO TBK PT
CMRY PT CISARUA MOUNTAIN DAIRY TBK
PGEO PERTAMINA GEOTHERMAL ENERGY
Z29 029 GROUP SE
- Johnny Yum
- Stevanus Juanda
Strategy - Catching A Falling Knife Or Opportunity To Buy? We Say Buy
We think the current trajectory of the JCI presents a buying opportunity as: a) it is now trading at -2SD PE, similar to the levels seen during the pandemic, although the current situation may not be as severe; b) GDP is still expected to rise above 5%; and c) many programmes are driven by the government. We add defensive names with strong growth and attractive valuations to our recommendations. Our picks are BBCA, BBTN, CMRY, ICBP, KLBF, CTRA, AMRT, PGEO, TLKM and ISAT.
KLBF PT KALBE FARMA TBK
AMRT SUMBER ALFARIA TRIJAYA TBK PT
BBCA PT BANK CENTRAL ASIA TBK
TLKM PT TELKOM INDONESIA (PERSERO) TBK CLASS B
ICBP INDOFOOD CBP SUKSES MAKMUR T
BBTN BANK TABUNGAN NEGARA PERSERO TBK PT
CMRY PT CISARUA MOUNTAIN DAIRY TBK
PGEO PERTAMINA GEOTHERMAL ENERGY
ISAT INDOSAT TBK PT
- Johnny Yum
- Maskun Ramli
- Stevanus Juanda
Indonesia Daily - Tuesday, February 11, 2025
Strategy: Catching A Falling Knife Or Opportunity To Buy? We Say Buy: Our picks are BBCA, BBTN, CMRY, ICBP, KLBF, CTRA, AMRT, PGEO, TLKM and ISAT. We have a lower end-25 target of 7,500 for the JCI. TRADERS’ CORNER Unilever Indonesia (UNVR IJ): Technical BUY Merdeka Copper Gold (MDKA IJ): Technical BUY
KLBF PT KALBE FARMA TBK
AMRT SUMBER ALFARIA TRIJAYA TBK PT
BBCA PT BANK CENTRAL ASIA TBK
TLKM PT TELKOM INDONESIA (PERSERO) TBK CLASS B
ICBP INDOFOOD CBP SUKSES MAKMUR T
BBTN BANK TABUNGAN NEGARA PERSERO TBK PT
CMRY PT CISARUA MOUNTAIN DAIRY TBK
PGEO PERTAMINA GEOTHERMAL ENERGY
ISAT INDOSAT TBK PT
- Johnny Yum
- Stevanus Juanda
Strategy - Trade War Begins
Donald Trump announced a 25% tariff on imports from Mexico and Canada. Imports of oil from Canada into the US are subject to a 10% tariff, in addition to an extra 10% tariff on imports from the US, Canada retaliated by imposing a 25% tariff on imports from the US, including beverages, cosmetics and paper products worth US$20b. Mexico and China are also expected to retaliate. The biggest risk is the potential underperformance of the JCI. Our top picks are ASII, BMRI, BBNI, BBTN, CMRY, KLBF, SIDO,...
KLBF PT KALBE FARMA TBK
BMRI PT BANK MANDIRI (PERSERO) TBK
ACES PT ACE HARDWARE INDONESIA TBK
ASII PT ASTRA INTERNATIONAL TBK
SIDO INDUSTRI JAMU DAN FARMASI SI
BBTN BANK TABUNGAN NEGARA PERSERO TBK PT
BBNI BANK NEGARA INDONESIA PERSER
GOTO GOJEK TOKOPEDIA TBK PT
CMRY PT CISARUA MOUNTAIN DAIRY TBK
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.